Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 3/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9425361 | 0.99 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL8799489 | 0.94 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL8799001 | 0.83 | LMNA (0.48) | PDE4APDE4BPDE4CPDE4DLMNA | |
| Hydrochloric Acid SCHEMBL9425417 | 0.82 | NPSR1 (0.47) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL8798987 | 0.82 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL11520095 | 0.82 | LMNA (0.51) | LMNANPSR1HPGDPIK3CASMN1; SMN2 | |
| SCHEMBL8312859 | 0.81 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL8050135 | 0.80 | NPSR1 (0.65) | PDE4ALMNANPSR1HPGDPIK3CA | |
| SCHEMBL8320258 | 0.80 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DNPSR1 | |
| SCHEMBL8471627 | 0.79 | NPSR1 (0.47) | PDE4APDE4BPDE4CPDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0527117-B1 | Substituted cyclopropylamino-1,3,5-triazines | UCB SA (BE) | 1997-10-29 | — | — | EP | claimed |
| US-5348956-A | Antiinflammatory and antiasthmatic agents | UCB S.A. (BE) | 1994-09-20 | — | — | US | claimed |
| US-5258513-A | FOR TREATMENT OF ALZHEIMER'S DISEASE, SENILE DEMENTIA, EVOLUTIVE COGNITIVE PATHOLOGIES, DEPRESSION, ANXIETY, MOOD DISTURBANCES, INFLAMMATION AND ASTHMA | UCB S.A. (BE) | 1993-11-02 | — | — | US | claimed |
| EP-0527117-A1 | Substituted cyclopropylamino-1,3,5-triazines | U C B, S.A. (BE) | 1993-02-10 | — | — | EP | claimed |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2559693-B1 | Polycyclic compound | EISAI R&D MAN CO LTD (JP) | 2014-11-26 | — | — | EP | disclosed |
| CN-102333777-B | Nitrogen-containing fused heterocyclic compounds and their use as beta-amyloid production inhibitors | EISAI R&D MAN CO LTD | 2014-06-25 | — | — | CN | disclosed |
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| CN-101815713-B | Polycyclic compounds | EISAI R&D MAN CO LTD | 2013-09-11 | — | — | CN | disclosed |
| EP-2615090-A1 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-2401276-B1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2010098495-A1 | IMIDAZOLYLPYRAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-0527117-B1 | Substituted cyclopropylamino-1,3,5-triazines | UCB SA (BE) | 1997-10-29 | — | — | EP | disclosed |
| US-5348956-A | Antiinflammatory and antiasthmatic agents | UCB S.A. (BE) | 1994-09-20 | — | — | US | disclosed |
| US-5258513-A | FOR TREATMENT OF ALZHEIMER'S DISEASE, SENILE DEMENTIA, EVOLUTIVE COGNITIVE PATHOLOGIES, DEPRESSION, ANXIETY, MOOD DISTURBANCES, INFLAMMATION AND ASTHMA | UCB S.A. (BE) | 1993-11-02 | — | — | US | disclosed |
| EP-0527117-A1 | Substituted cyclopropylamino-1,3,5-triazines | U C B, S.A. (BE) | 1993-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | PDE4A 1337/4885PDE4B 1780/4885PDE4C 1811/4885 |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | PDE4A 89/4885PDE4B 215/4885PDE4C 187/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | PDE4A 2370/4885PDE4B 2486/4885PDE4C 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.